Marker Therapeutics, Inc. (MRKR)

ich glaube weder hier noch dort daran  

warum glaubst du bei Axsome nicht daran ?? Die haben ihr Ding mit Major Depression mit Breakthrouh Therapy Designation doch so gut wie durch ????  

Erkrankungen sind aufgrund der Placebo Wirkung leicht unbeabsichtigt zu verfälschen und in Phase 3 schwer zu verifizieren. Letzteres ist aber dann die Zulassungsvoraussetzung mitI Doppelblind Versuchen und dort trennt sich dann meist die Spreu vom Korn / Placebo.
Würde mich freuen, wenn es dort anders wäre.
Meine Meinung - KEINE Handelsempfehlung.  

https://www.analystratings.com/articles/...-marker-therapeutics-mrkr/  

monat. Deine Pieris ist wohl doch nicht das gelbe vom Ei,hm Itechdachs ???

HOUSTON, May 13, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that updated clinical data from an investigator-sponsored Phase 1/2 trial led by Baylor College of Medicine were selected for presentation during a poster session at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting. ASCO 2020 will be held virtually from Friday, May 29 through Sunday, May 31, 2020. The data will be presented by lead investigator, Brandon G. Smaglo, M.D., FACP.  

Marker Therapeutics, Inc. (PRNewsfoto/Marker Therapeutics, Inc.)
Marker Therapeutics, Inc. (PRNewsfoto/Marker Therapeutics, Inc.)
More
Presentation Details

Title: "A phase I trial targeting advanced or metastatic pancreatic cancer using a combination of standard chemotherapy and adoptively transferred nonengineered, multiantigen specific T cells in the first-line setting (TACTOPS)"
Authors: Smaglo BG, et al.
Session Type: Poster Session
Session Title: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract: 4622
Poster: 230

The presentation will be available on demand to ASCO registrants beginning May 29, 2020 at 8:00 a.m. ET. The poster will be available in the Investors section of the Company's website at markertherapeutics.com.

About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies  

als Marker - bislang waren alle klinischen Meilensteine eine Enttäuschung für Marker, aber sie können mit dem Lead-Produkt in Bauchspeicheldrüsenkrebs ja Ende des Monats nochmal das Blatt wenden.
Bei Pieris dagegen ist der Fahrplan trotz einiger nicht über die Anfangsphasen weitergeführter Projekte recht eindeutig und sollte mit dem Start der Phase II durch Astrazeneca wieder richtig loslegen.
Meine Meinung - KEINE Handelsempfehlung.  

jau,machenb wir uns nix vor,marker und pieris sind 2 interssante Aktien,aber ich glaube nicht,dass Marker irgendwie schlechter dasteht als Pieris  

Pieris macht schon 45 mln Umsatzt ,wusst ich garnicht,womit eigentlich ????  

bezahlen und haben gegebenenfalls die Möglichkeit Teile in späteren Phasen zurückzukaufen, z.B. für PRS-060 nach der Phase 2 die noch komplett von AstraZeneca bezahlt wird.  

gut,hab mir die Pipeline von Pieris angeschaut,ganz gut und Bosten Massachusetts ist ja auch erste Adresse,aber alles erst in Phase 1 und das stört mich wie lange willst du denn warten bis sich da mal was tut ?????  

bei Marker kommen ja vielleicht neue Daten zur Studie bei Bauchspeicheldrüsenkrebs. Damit wurde die Aktie ja schon einmal gehypt, obwohl die Ergebnisse allein durch die Vorauswahl der Patienten zu erklären waren. Diesmal dürfte die Hürde etwas höher liegen und der Markt entsprechend skeptischer auf Hype von Seitens des CEO reagieren.
Bei Pieris sind die Ergebnisse ja schon vorgezeichnet und der Kurs dürfte nur auf eine Meldung der Phase 2 durch AstraZeneca warten.
Meine Meinung - KEINE Handelsempfehlung.  

Bisher ohne Kursreaktion
--
https://www.markertherapeutics.com/2020/05/...-asco-virtual-annual-m/
MARKER THERAPEUTICS REPORTS INTERIM RESULTS OF ITS MULTITAA-SPECIFIC T CELL THERAPY IN PATIENTS WITH PANCREATIC ADENOCARCINOMA AT THE 2020 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) VIRTUAL ANNUAL MEETING
MAY 29, 2020
...
https://meetinglibrary.asco.org/record/186395/abstract
 

Marker Therapeutics Receives USAN Approval for "zelenoleucel" as Nonproprietary Name for MT-401, Multi-Tumor-Associated Antigen Targeted T Cell Product for Acute Myeloid Leukemia
PR Newswire PR NewswireJune 23, 2020

HOUSTON, June 23, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced today that the United States Adopted Names (USAN) Council has approved  "zelenoleucel" as the nonproprietary (generic) name for MT-401, a multi-tumor-associated antigen (MultiTAA)-specific T cell product candidate for the treatment of patients with acute myeloid leukemia (AML) following allogeneic stem cell transplant in both adjuvant and active disease settings.

Marker Therapeutics, Inc. (PRNewsfoto/Marker Therapeutics, Inc.)
Marker Therapeutics, Inc. (PRNewsfoto/Marker Therapeutics, Inc.)
More
"The USAN approval of zelenoleucel as the generic name for MT-401 is another step forward for continued advancement of our therapy," said Peter L. Hoang, President & CEO of Marker Therapeutics. "MT-401, which received Orphan Drug designation from the U.S. FDA in April, has shown clinical benefit in patients with acute myeloid leukemia post stem cell transplant in an investigator-sponsored trial. We are excited about the continued clinical development of zelenoleucel and look forward to initiating our Company-sponsored Phase 2 study in patients with AML following transplant."

About USAN

The United States Adopted Names (USAN) Council is responsible for selecting simple, informative and unique nonproprietary (generic) drug names. The USAN Council establishes logical nomenclature classifications based on pharmacological and/or chemical relationships. In addition to one member-at-large and a Food and Drug Administration (FDA) liaison, the council consists of one representative from each of the following: The American Medical Association, United States Pharmacopeia (USP) and the American Pharmacists Association.

About MultiTAA-Specific T Cell Therapy

Marker's Multi-Tumor-Associated Antigen Targeted (MultiTAA) platform is a novel, non-genetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient's blood capable of recognizing a broad range of tumor antigens. In early clinical trials, the multi-antigen approach has been well-tolerated and shown to enhance tumor destroying capability of T cells. It is one of the first therapies to consistently demonstrate epitope-spreading – inducing the patient's own T cells to expand, potentially contributing to a lasting anti-tumor effect. Unlike other cell therapies which require pre-conditioning regimens and hospitalization, MultiTAA-specific T cells are designed to be administered in an outpatient setting.  

da hat ein Komitee sich auf Wunsch der Firma einen Namen ausgedacht und schon bringt man den als Pressemitteilung unters Volk.
Mir kommt da die Frage "Haben die nichts besseres zu tun? - offensichtlich nicht.

Meine Meinung - KEINE Handelsempfehlung.  

sag mal Itechdachs,was hälst du eigentlich von Advaxis ? Die Krebstherapien sollen vielversprechend sein und das Teil ist nur 34 mio wert ?????  

und was hälst du von Aptevo Therapeutics Inc. (APVO),commercial stage für schlappe 25 mio ???  

Marker Therapeutics Announces New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates
PR Newswire PR Newswire•June 30, 2020
-- Facility expected to be built by year-end, fully operational in 2021 --




HOUSTON, June 30, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it has executed a lease agreement to establish a cGMP manufacturing facility in Houston, TX, in an area near the George Bush Intercontinental Airport. The facility will allow production according to U.S. Food and Drug Administration (FDA) guidelines and is designed to be scalable using modular processes. The facility is expected to be completed by year-end and operational in 2021.

Marker Therapeutics, Inc. (PRNewsfoto/Marker Therapeutics, Inc.)
Marker Therapeutics, Inc. (PRNewsfoto/Marker Therapeutics, Inc.)
More
"We are committed to the rapid advancement of Marker's MultiTAA-specific T cell therapies, which have demonstrated impressive responses in clinical studies across both hematological and solid tumors," said Peter L. Hoang, President & CEO of Marker Therapeutics. "With the build-out of our own internal manufacturing capabilities, we will have the flexibility to support our AML trial, and future hematological and solid tumor trials, as well as the potential commercialization of our products."

The facility has approximately 48,500 feet and will provide space for clinical manufacturing and quality functions upon completion. Marker will continue to manufacture its MultiTAA-specific T cell therapy at the Baylor College of Medicine to support the Company-sponsored AML trial until the in-house cGMP manufacturing facility is operational.

Commented Anthony Kim, Marker's Chief Financial Officer: "Commencing the build-out of our internal cGMP facility strategically fits Marker's expansion plans and is an exciting next step as we initiate our first Company-sponsored clinical trial in patients with AML following transplant.  

Manchmal geht es dann schneller als man denkt - und ohne zu wissen warum. Egal, mein Depots (und Investor 2021-Spiel) freuts .. :)
 

MARKER THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 2 TRIAL OF MT-401 IN ACUTE MYELOID LEUKEMIA FOLLOWING STEM CELL TRANSPLANT
MARCH 3, 2021
"TOPLINE READOUT OF ACTIVE DISEASE GROUP IN AML TRIAL EXPECTED IN Q1 2022
Houston, TX – March 3, 2021– Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced it has treated the first patient in the Company’s Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate. The trial is enrolling patients with acute myeloid leukemia (AML) following an allogeneic stem cell transplant in both the adjuvant and active disease settings..."
https://www.markertherapeutics.com/2021/03/...g-stem-cell-transplant/
--
Startschuss für die nächste Welle !?
 

Klinisch gefällt mir das sehr gut, aber da wird wohl bald die nächste KE fällig.. !?

https://www.markertherapeutics.com/2021/03/...-and-financial-results/
 

Es kommt tatsächlich eine KE. Unbekanntes Ausmaß...
Kurs knickt ein..
https://www.ariva.de/news/...nounces-proposed-public-offering-9252411